Researcher profile

Paula L. McClean

Paula L. McClean contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author
3works
0followers
6topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2020arXiv

Computational neurology: Computational modeling approaches in dementia

Dementia is a collection of symptoms associated with impaired cognition and impedes everyday normal functioning. Dementia, with Alzheimer's disease constituting its most common type, is highly complex in terms of etiology and pathophysiology. A more quantitative or computational attitude towards dementia research, or more generally in neurology, is becoming necessary - Computational Neurology. We provide a focused review of some computational approaches that have been developed and applied to the study of dementia, particularly Alzheimer's disease. Both mechanistic modeling and data-drive, including AI or machine learning, approaches are discussed. Linkage to clinical decision support systems for dementia diagnosis will also be discussed.

preprint2020arXiv

Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease

Alzheimer's disease (AD) is an age-specific neurodegenerative disease that compromises cognitive functioning and impacts the quality of life of an individual. Pathologically, AD is characterised by abnormal accumulation of beta-amyloid (A$β$) and hyperphosphorylated tau protein. Despite research advances over the last few decades, there is currently still no cure for AD. Although, medications are available to control some behavioural symptoms and slow the disease's progression, most prescribed medications are based on cholinesterase inhibitors. Over the last decade, there has been increased attention towards novel drugs, targeting alternative neurotransmitter pathways, particularly those targeting serotonergic (5-HT) system. In this review, we focused on 5-HT receptor (5-HTR) mediated signalling and drugs that target these receptors. These pathways regulate key proteins and kinases such as GSK-3 that are associated with abnormal levels of A$β$ and tau in AD. We then review computational studies related to 5-HT signalling pathways with the potential for providing deeper understanding of AD pathologies. In particular, we suggest that multiscale and multilevel modelling approaches could potentially provide new insights into AD mechanisms, and towards discovering novel 5-HTR based therapeutic targets.

preprint2020arXiv

Predicting feature imputability in the absence of ground truth

Data imputation is the most popular method of dealing with missing values, but in most real life applications, large missing data can occur and it is difficult or impossible to evaluate whether data has been imputed accurately (lack of ground truth). This paper addresses these issues by proposing an effective and simple principal component based method for determining whether individual data features can be accurately imputed - feature imputability. In particular, we establish a strong linear relationship between principal component loadings and feature imputability, even in the presence of extreme missingness and lack of ground truth. This work will have important implications in practical data imputation strategies.